Neox Biotech

neoX Biotech (星亢原生物) is a Chinese biotech company founded in 2018 by CEO Hang Chen and others, positioning itself as the country's first to focus on AI-driven biologic drug development . The company combines artificial intelligence, biophysics, and high-throughput experimentation to design drugs from the ground up, with particular emphasis on large-molecule therapeutics and PROTAC protein degraders .

The company has raised substantial venture backing across multiple rounds. It closed a $30 million Series A in early 2021 led by Sky9 Capital and 5Y Capital, followed by an A+ round within six months that brought cumulative funding to nearly $100 million . 5Y Capital, an early and repeated backer, has participated in all four funding rounds from angel through A+ . Other investors include Sequoia China, Yuanjing Capital, BAI Capital, Vertex Ventures China, and later HongShan (formerly Sequoia China) .

By mid-2021, neoX had established R&D centers in Beijing's Zhongguancun Life Science Park and Shanghai's Zhangjiang, and had begun translating its computational platform into proprietary drug assets alongside partnerships with major pharmaceutical firms . The company was recognized by *MIT Technology Review* with a "Best Innovation" award in 2020 .